4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Vascular Dementia
Chang Gung Memorial HospitalSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Vascular Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pittsburgh Compound B Unlabelled National Taiwan University Hospital | Phase 4 | BB |
Cilostazol Peking University First Hospital | Phase 4 | BB |
Risperidone Janssen-Cilag Pty Ltd | Phase 3 | BB |
Oxycodone Hydrochloride, Hydrocodone- VA Office of Research and Development | Phase 4 | BB |
Aspirin Peking University First Hospital | Phase 4 | BB |
View all 40 →
Same molecule, other indications
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →